This record was last updated December 9, 2024 (before its estimated December 20, 2024 completion). Its status may not reflect the trial's current state.
Summary
The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops (available under brand name VIZILOTON) to prevent the progression of grade I and II senile cataract.
This study could answer:
* Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract?
* The acceptance/ compliance of participants to taurine-containing eye drops.
* Could long-term use of taurine-containing eye drops cause adverse effect(s)?
Participants will:
* Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year.
* Visit eye clinic every 3 months for assessment and visual examination.
* Keep notes for their symptoms and their adherence to treatment.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-10.